MYC and neoplasm: While MYC overexpression reduces response to anti-PD-L1, MYC inactivation in combination with anti-PD-L1 delayed tumor recurrence and extended survival in mice, suggesting that MYC expression enhances tumor immune evasion and reduces efficacy of PD-1 blockade as a monotherapy.